GlassScriptPhysician profile
Aasems Jacob
NPI 1447633284
$18,735.38
in general payments reported to CMS, 2019-2025
54 companies · $2,761 in 2025
The $2,761 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $90.83 · 2021: $855 · 2022: $1,140 · 2023: $3,135 · 2024: $11K · 2025: $2,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,930 · Food and Beverage: $5,540 · Travel and Lodging: $954 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,930.00 |
| Food and Beverage | $5,539.78 |
| Travel and Lodging | $954.30 |
| Education | $224.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,696.81 | 2021-2025 | Imfinzi, Tagrisso, Calquence |
| Incyte Corporation | $1,712.06 | 2021-2025 | Monjuvi, Zynyz, Pemazyre |
| Janssen Scientific Affairs, LLC | $1,635.00 | 2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $820.65 | 2021-2025 | |
| Beigene USA, INC. | $703.10 | 2021-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $625.66 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $441.39 | 2020-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $429.94 | 2021-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $414.06 | 2021-2025 | Enhertu, Injectafer |
| Pfizer INC. | $377.65 | 2021-2025 | |
| Abbvie INC. | $361.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $281.92 | 2021-2025 | Zejula, Ojjaara |
| Amgen INC. | $280.28 | 2021-2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $259.12 | 2021-2024 | Libtayo |
| Sobi, INC | $222.22 | 2024 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $206.50 | 2021-2024 | |
| Celgene Corporation | $159.74 | 2021-2024 | Reblozyl, Opdualag, Pomalyst |
| Astellas Pharma US INC | $152.65 | 2022-2025 | Vyloy |
| Seagen INC. | $136.00 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Adaptive Biotechnologies Corporation | $114.10 | 2021-2023 | Clonoseq |
| Genzyme Corporation | $111.62 | 2023-2024 | |
| Array Biopharma INC | $106.23 | 2021-2024 | Braftovi, Mektovi, Xalkori |
| Lilly USA, LLC | $104.09 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $93.44 | 2021-2025 | Polivy, Phesgo, Tecentriq |
| Puma Biotechnology, INC. | $87.30 | 2021-2024 | |
| Eisai INC. | $86.49 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $86.30 | 2022-2023 | Xpovio |
| Genmab U.S., INC. | $81.80 | 2023-2024 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $81.07 | 2022-2024 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $77.95 | 2021-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $74.46 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $68.06 | 2025 | |
| Emd Serono, INC. | $60.45 | 2021-2025 | Bavencio, Tepmetko |
| Pharmacosmos Therapeutics INC. | $56.82 | 2023-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $55.69 | 2022-2024 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $44.54 | 2024 | Orserdu |
| Exelixis INC. | $42.89 | 2024-2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $40.97 | 2024 | |
| Sumitomo Pharma America, INC. | $35.11 | 2024-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $33.86 | 2025 | Ultomiris |
| Adc Therapeutics America, INC. | $33.14 | 2022-2023 | |
| Pharmaessentia USA Corporation | $30.79 | 2025 | Besremi |
| Kyowa Kirin, INC. | $29.22 | 2023-2024 | Poteligeo |
| Novocure INC. | $27.22 | 2022-2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.59 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.66 | 2023 | Tazverik |
| Coherus Oncology, INC. | $17.79 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.73 | 2023 | Pyrukynd |
| Blueprint Medicines Corporation | $14.62 | 2023 | Ayvakit |
| Dova Pharmaceuticals | $13.58 | 2021 | |
| Tersera Therapeutics LLC | $13.46 | 2023 | Zoladex |
| Mirati Therapeutics, INC. | $13.12 | 2024 | Krazati |
| G1 Therapeutics, INC. | $12.53 | 2022 | |
| Medtronic, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aasems Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.